Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. BMI greater than or equal (\>=) to 27 kilogram per meter square (kg/m\^2)~2. Subjects able and willing to comply with a reduced-calorie diet and an increased physical activity program~3. Age \>= to 40 years with established CV disease as defined by one of the following:~   1. History of documented MI or ischemic stroke~  2. History of peripheral artery disease~  3. History of revascularization (coronary, carotid, or peripheral artery)~  4. Significant unrevascularized coronary arterial stenosis~OR~Age \>= to 55 years for women or \>= to 50 years for men who have type 2 diabetes mellitus (T2DM) without established CV disease plus at least one of the following CV risk factors:~1. Hypertension, or currently receiving therapy for documented hypertension~2. Dyslipidemia, or currently taking prescription lipid-lowering therapy for documented dyslipidemia~3. Estimated glomerular filtration rate \>= to 30 to less than equal (\<=) to 60 mililitre per minute per 1.73 meter square (mL/min/1.73 m\^) per the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation~4. High high sensitivity C-reactive protein (hsCRP)~5. Urinary albumin-to-creatinine ratio (ACR) \>= 30 ug/mg~Subjects with T2DM may have a pre-existing or new diagnosis of T2DM. A new diagnosis of T2DM (ie, discovered at Screening) should be based on the 2013 American Diabetes Association (ADA) guidelines.~All T2DM subjects must have an HbA\[1c\] less (\<) than 10% at Screening. If subjects are being treated, or upon diagnosis need to be treated with antidiabetic agents, the T2DM treatment regimen must be stable for at least 3 months prior to randomization.~Exclusion Criteria~1. Moderate or greater symptoms of congestive cardiac failure (New York Heart Association \[NYHA\] class III or IV)~2. Known left ventricular (LV) ejection fraction \< than 20%~3. Moderate or greater symptoms of pulmonary hypertension (PH)~4. Known severe valvular disease~5. Moderate renal impairment, severe renal impairment (estimated glomerular filtration rate \< 30 mL/min/1.73 m\^ per the CKD-EPI equation based on ideal body weight), or end stage renal disease (ESRD)~6. Severe hepatic impairment~7. Use of other products intended for weight loss including prescription drugs, over-the-counter (OTC) drugs, and herbal preparations~8. Use of more than one other serotonergic drug~9. Use of drugs known to increase the risk for cardiac valvulopathy within 6 months prior to Screening including, but not limited to: pergolide, ergotamine, methysergide, cabergoline~10. History or evidence of clinically significant disease (e.g., malignancy, cardiac, respiratory, gastrointestinal, renal or psychiatric disease)~11. Use of lorcaserin HCl prior to Screening or hypersensitivity to lorcaserin HCl or any of the excipients~12. Planned bariatric surgery~13. Females must not be breastfeeding or pregnant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lorcaserin hydrochloride (HCL)10 mg (Type: EXPERIMENTAL): APD356 10 mg twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).